Merck Cost of Goods Sold 2010-2024 | MRK
Merck annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- Merck cost of goods sold for the quarter ending September 30, 2024 was $4.080B, a 4.32% decline year-over-year.
- Merck cost of goods sold for the twelve months ending September 30, 2024 was $15.277B, a 5.08% decline year-over-year.
- Merck annual cost of goods sold for 2023 was $16.126B, a 7.38% decline from 2022.
- Merck annual cost of goods sold for 2022 was $17.411B, a 27.78% increase from 2021.
- Merck annual cost of goods sold for 2021 was $13.626B, a 0.06% increase from 2020.
Merck Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$16,126 |
| 2022 |
$17,411 |
| 2021 |
$13,626 |
| 2020 |
$13,618 |
| 2019 |
$12,016 |
| 2018 |
$13,509 |
| 2017 |
$12,912 |
| 2016 |
$14,030 |
| 2015 |
$14,934 |
| 2014 |
$16,768 |
| 2013 |
$16,954 |
| 2012 |
$16,446 |
| 2011 |
$16,871 |
| 2010 |
$18,396 |
| 2009 |
$9,019 |
Merck Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-09-30 |
$4,080 |
| 2024-06-30 |
$3,745 |
| 2024-03-31 |
$3,540 |
| 2023-12-31 |
$3,912 |
| 2023-09-30 |
$4,264 |
| 2023-06-30 |
$4,024 |
| 2023-03-31 |
$3,926 |
| 2022-12-31 |
$3,881 |
| 2022-09-30 |
$3,934 |
| 2022-06-30 |
$4,216 |
| 2022-03-31 |
$5,380 |
| 2021-12-31 |
$3,873 |
| 2021-09-30 |
$3,450 |
| 2021-06-30 |
$3,104 |
| 2021-03-31 |
$3,199 |
| 2020-12-31 |
$4,546 |
| 2020-09-30 |
$3,013 |
| 2020-06-30 |
$2,747 |
| 2020-03-31 |
$3,312 |
| 2019-12-31 |
$1,573 |
| 2019-09-30 |
$3,990 |
| 2019-06-30 |
$3,401 |
| 2019-03-31 |
$3,052 |
| 2018-12-31 |
$3,289 |
| 2018-09-30 |
$3,619 |
| 2018-06-30 |
$3,417 |
| 2018-03-31 |
$3,184 |
| 2017-12-31 |
$3,440 |
| 2017-09-30 |
$3,307 |
| 2017-06-30 |
$3,116 |
| 2017-03-31 |
$3,049 |
| 2016-12-31 |
$3,471 |
| 2016-09-30 |
$3,409 |
| 2016-06-30 |
$3,578 |
| 2016-03-31 |
$3,572 |
| 2015-12-31 |
$3,850 |
| 2015-09-30 |
$3,761 |
| 2015-06-30 |
$3,754 |
| 2015-03-31 |
$3,569 |
| 2014-12-31 |
$3,749 |
| 2014-09-30 |
$4,223 |
| 2014-06-30 |
$4,893 |
| 2014-03-31 |
$3,903 |
| 2013-12-31 |
$4,607 |
| 2013-09-30 |
$4,104 |
| 2013-06-30 |
$4,284 |
| 2013-03-31 |
$3,959 |
| 2012-12-31 |
$4,160 |
| 2012-09-30 |
$4,137 |
| 2012-06-30 |
$4,112 |
| 2012-03-31 |
$4,037 |
| 2011-12-31 |
$4,176 |
| 2011-09-30 |
$4,352 |
| 2011-06-30 |
$4,284 |
| 2011-03-31 |
$4,059 |
| 2010-12-31 |
$4,440 |
| 2010-09-30 |
$4,191 |
| 2010-06-30 |
$4,549 |
| 2010-03-31 |
$5,216 |
| 2009-12-31 |
$4,901 |
| 2009-09-30 |
$1,430 |
| 2009-06-30 |
$1,354 |
| 2009-03-31 |
$1,334 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$244.211B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
